Analyst: Buy This Battered Healthcare Stock

Analysts are overwhelmingly bullish on Athenex

May 2, 2019 at 11:19 AM
facebook twitter linkedin

Oppenheimer initiated coverage on Athenex Inc (NASDAQ:ATNX) with an "outperform" rating and $20 price target -- a nearly 112% premium to last night's close at $9.44. The covering analyst waxed optimistic on positive data for the biopharmaceutical firm's specialty oncology products, as well as positive late-stage Oraxol breast cancer data.

Analysts are already upbeat on ATNX, with 100% of those in coverage maintaining a "buy" or better rating. Plus, the average 12-month price target sits all the way up at $25.58.

Short sellers, on the other hand, have been ramping up their bearish exposure to the stock. Short interest rose 3% in the most recent reporting period to 5.33 million shares. This represents 16% of Athenex's available float, or 16.3 times the average daily pace of trading.

Looking at the charts, these bears have certainly been in the driver's seat. Even with today's 5.9% pop to trade at $9.99, ATNX stock is still down 37.2% year-over-year. Plus, the shares hit a record low of $9.38 yesterday. As such, the equity's 14-day Relative Strength Index (RSI) closed Wednesday at 27, suggesting the oversold stock may have been due for a short-term bounce.


Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

Schaeffer's Daily Bulletin Offer


Special Offers from Schaeffer's Trading Partners